First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer
Hoersholm, Denmark, June 26, 2018 – Oncology Venture AB (OV:ST), Oncology Venture US Inc. (former 2X Oncology, Inc.) and Medical Prognosis Institute A/S (MPI:ST) announces dosing of the first patient in a Phase 2 clinical study to investigate the anti-tumor effect and tolerability of 2X-121 in patients with metastatic breast cancer selected by a novel drug response predictor (DRP®) mRNA driven multiple biomarker, the 2X-121 DRP®.2X-121 is a PARP inhibitor. This clinical trial will enroll metastatic Breast Cancer patients, who have relapsed on two or more different prior therapies. The 2X-